Research programme: ion channel and GABA A modulators - Saniona

Drug Profile

Research programme: ion channel and GABA A modulators - Saniona

Alternative Names: AN 346; AN 363; AN 470; AN 761; AN-726; NS9283; NSD-708; NSD-761; NSD-847; NSD-867

Latest Information Update: 27 May 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline; NeuroSearch
  • Developer Saniona
  • Class
  • Mechanism of Action Alpha4beta2 nicotinic receptor modulators; Alpha7 nicotinic acetylcholine receptor agonists; GABA A alpha 2 receptor modulators; GABA A alpha 3 receptor modulators; GABA A receptor modulators; GABA modulators; Intermediate conductance calcium activated potassium channel modulators; Ion channel modulators; Small conductance calcium activated potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; CNS disorders; Dyskinesias; Inflammatory bowel diseases; Neuropathic pain; Schizophrenia

Most Recent Events

  • 27 May 2016 Saniona suspends a phase II trial for AN 363 in Neuropathic pain in Netherlands and Holland
  • 26 May 2016 Saniona suspends a phase I trial for AN 363 in Neuropathic pain in Netherlands and Holland
  • 14 Sep 2015 Preclinical development for Neuropathic pain is ongoing in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top